Top

Published in:

01-09-2014 | Preclinical study

High NR2F2 transcript level is associated with increased survival and its expression inhibits TGF-β-dependent epithelial-mesenchymal transition in breast cancer

Authors: Cheng Zhang, Yong Han, Hao Huang, Like Qu, Chengchao Shou

Published in: Breast Cancer Research and Treatment | Issue 2/2014

Abstract

NR2F2, a member of nuclear receptor subfamily 2, was shown to be associated with cancer, but its role in breast malignancy remains unclear. In this study, we aimed to explore the function of NR2F2 in breast cancer. We browsed GEO and TCGA databases and used Kaplan–Meier survival analysis to explore the association between NR2F2 transcript level and patient survival in breast cancer. NR2F2 expression in breast cancer tissues was evaluated by immunohistochemistry staining. NR2F2-related functions and its role in Epithelial-Mesenchymal Transition (EMT) were predicted by Gene Set Enrichment Analysis (GSEA) and validated by in vitro assays with NR2F2 knockdown MDA-MB231 and MCF7 cells. We found high NR2F2 transcript level was correlated with favorable overall survival and distant metastasis-free survival. Positive rate of NR2F2 protein tended to be decreased with the progression of malignancy. Results of in vitro migration and invasion assays suggested NR2F2’s potential in inhibiting invasiveness. NR2F2 was predicted to be negatively linked with EMT and TGF-β-pathway related genes, which was supported by observation of EMT-like morphology and changes in EMT-markers E-cadherin and Slug. Additionally, we found TGF-β inhibited the expression of NR2F2. GSEA also predicted that NR2F2 could be inversely associated with chemoresistance, which was verified by results of in vitro growth inhibition assays using chemotherapeutic agents. Our results demonstrated high NR2F2 transcript level was associated with favorable clinical outcome, which might be due to NR2F2’s inhibitory effect on TGF-β-dependent EMT and its role in inhibiting chemoresistance.

You LR, Takamoto N, Yu CT, Tanaka T, Kodama T, Demayo FJ, Tsai SY, Tsai MJ (2005) Mouse lacking COUP-TFII as an animal model of Bochdalek-type congenital diaphragmatic hernia. Proc Natl Acad Sci USA 102(45):16351–16356. doi:10.1073/pnas.0507832102 PubMedCentralPubMedCrossRef

Pereira FA, Qiu Y, Zhou G, Tsai MJ, Tsai SY (1999) The orphan nuclear receptor COUP-TFII is required for angiogenesis and heart development. Genes Dev 13(8):1037–1049PubMedCentralPubMedCrossRef

Lin B, Chen GQ, Xiao D, Kolluri SK, Cao X, Su H, Zhang XK (2000) Orphan receptor COUP-TF is required for induction of retinoic acid receptor beta, growth inhibition, and apoptosis by retinoic acid in cancer cells. Mol Cell Biol 20(3):957–970PubMedCentralPubMedCrossRef

Qin J, Chen X, Xie X, Tsai MJ, Tsai SY (2010) COUP-TFII regulates tumor growth and metastasis by modulating tumor angiogenesis. Proc Natl Acad Sci USA 107(8):3687–3692. doi:10.1073/pnas.0914619107 PubMedCentralPubMedCrossRef

Qin J, Chen X, Yu-Lee LY, Tsai MJ, Tsai SY (2010) Nuclear receptor COUP-TFII controls pancreatic islet tumor angiogenesis by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor-2 signaling. Cancer Res 70(21):8812–8821. doi:10.1158/0008-5472.can-10-0551 PubMedCentralPubMedCrossRef

Navab R, Gonzalez-Santos JM, Johnston MR, Liu J, Brodt P, Tsao MS, Hu J (2004) Expression of chicken ovalbumin upstream promoter-transcription factor II enhances invasiveness of human lung carcinoma cells. Cancer Res 64(15):5097–5105. doi:10.1158/0008-5472.can-03-1185 PubMedCrossRef

Qin J, Wu SP, Creighton CJ, Dai F, Xie X, Cheng CM, Frolov A, Ayala G, Lin X, Feng XH, Ittmann MM, Tsai SJ, Tsai MJ, Tsai SY (2013) COUP-TFII inhibits TGF-beta-induced growth barrier to promote prostate tumorigenesis. Nature 493(7431):236–240. doi:10.1038/nature11674 PubMedCentralPubMedCrossRef

Litchfield LM, Riggs KA, Hockenberry AM, Oliver LD, Barnhart KG, Cai J, Pierce WM Jr, Ivanova MM, Bates PJ, Appana SN, Datta S, Kulesza P, McBryan J, Young LS, Klinge CM (2012) Identification and characterization of nucleolin as a COUP-TFII coactivator of retinoic acid receptor beta transcription in breast cancer cells. PLoS ONE 7(5):e38278. doi:10.1371/journal.pone.0038278 PubMedCentralPubMedCrossRef

Litchfield LM, Klinge CM (2012) Multiple roles of COUP-TFII in cancer initiation and progression. J Mol Endocrinol 49(3):R135–R148. doi:10.1530/JME-12-0144 PubMedCentralPubMedCrossRef

10.

Nakshatri H, Mendonca MS, Bhat-Nakshatri P, Patel NM, Goulet RJ Jr, Cornetta K (2000) The orphan receptor COUP-TFII regulates G2/M progression of breast cancer cells by modulating the expression/activity of p21(WAF1/CIP1), cyclin D1, and cdk2. Biochem Biophys Res Commun 270(3):1144–1153. doi:10.1006/bbrc.2000.2562 PubMedCrossRef

11.

More E, Fellner T, Doppelmayr H, Hauser-Kronberger C, Dandachi N, Obrist P, Sandhofer F, Paulweber B (2003) Activation of the MAP kinase pathway induces chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) expression in human breast cancer cell lines. J Endocrinol 176(1):83–94PubMedCrossRef

12.

Nagasaki S, Suzuki T, Miki Y, Akahira J, Shibata H, Ishida T, Ohuchi N, Sasano H (2009) Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: possible regulator of lymphangiogenesis via vascular endothelial growth factor-C expression. Cancer Sci 100(4):639–645. doi:10.1111/j.1349-7006.2008.01078.x PubMedCrossRef

13.

Prahalad P, Dakshanamurthy S, Ressom H, Byers SW (2010) Retinoic acid mediates regulation of network formation by COUP-TFII and VE-cadherin expression by TGFbeta receptor kinase in breast cancer cells. PLoS ONE 5(4):e10023. doi:10.1371/journal.pone.0010023 PubMedCentralPubMedCrossRef

14.

Litchfield LM, Appana SN, Datta S, Klinge CM (2014) COUP-TFII inhibits NFkappaB activation in endocrine-resistant breast cancer cells. Mol Cell Endocrinol 382(1):358–367. doi:10.1016/j.mce.2013.10.010 PubMedCrossRef

15.

Ur-Rehman S, Gao Q, Mitsopoulos C, Zvelebil M (2013) ROCK: a resource for integrative breast cancer data analysis. Breast Cancer Res Treat 139(3):907–921. doi:10.1007/s10549-013-2593-z PubMedCrossRef

16.

Zhang C, Han Y, Huang H, Min L, Qu L, Shou C (2014) Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer. Int J Oncol 44(6):2025–2033. doi:10.3892/ijo.2014.2352 PubMed

17.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545–15550. doi:10.1073/pnas.0506580102 PubMedCentralPubMedCrossRef

18.

da Huang W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37(1):1–13. doi:10.1093/nar/gkn923 PubMedCentralCrossRef

19.

Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68(4):989–997. doi:10.1158/0008-5472.can-07-2017 PubMedCrossRef

20.

Karakas B, Weeraratna A, Abukhdeir A, Blair BG, Konishi H, Arena S, Becker K, Wood W 3rd, Argani P, De Marzo AM, Bachman KE, Park BH (2006) Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells. Oncogene 25(40):5561–5569. doi:10.1038/sj.onc.1209540 PubMedCrossRef

21.

Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, Yoo BC, Kim HK, Park JG (2004) Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 10(1 Pt 1):272–284PubMedCrossRef

22.

Li W, Wei W, Zhu S, Zhu J, Shi Y, Lin T, Hao E, Hayek A, Deng H, Ding S (2009) Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 4(1):16–19. doi:10.1016/j.stem.2008.11.014 PubMedCrossRef

23.

Zavadil J, Bottinger EP (2005) TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24(37):5764–5774. doi:10.1038/sj.onc.1208927 PubMedCrossRef

24.

Liu X, Zhang X, Lee I (2010) A quantitative study on morphological responses of osteoblastic cells to fluid shear stress. Acta Biochim Biophys Sin 42(3):195–201. doi:10.1093/abbs/gmq004 PubMedCrossRef

25.

Horikawa A, Okada K, Sato K, Sato M (2000) Morphological changes in osteoblastic cells (MC3T3-E1) due to fluid shear stress: cellular damage by prolonged application of fluid shear stress. Tohoku J Exp Med 191(3):127–137PubMedCrossRef

26.

Butte A (2002) The use and analysis of microarray data. Nat Rev Drug Discov 1(12):951–960. doi:10.1038/nrd961 PubMedCrossRef

27.

van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009. doi:10.1056/NEJMoa021967 PubMedCrossRef

28.

Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d’Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13(11):3207–3214. doi:10.1158/1078-0432.ccr-06-2765 PubMedCrossRef

29.

Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B, Maerevoet M, Vindevoghel A, Rouas G, Lallemand F, Durbecq V, Cardoso F, Salgado R, Rovere R, Bontempi G, Michiels S, Buyse M, Nogaret JM, Qi Y, Symmans F, Pusztai L, D’Hondt V, Piccart-Gebhart M, Sotiriou C (2011) Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 29(12):1578–1586. doi:10.1200/jco.2010.31.2231 PubMedCrossRef

30.

Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacon JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O’Shaughnessy J, Hortobagyi GN, Symmans WF (2011) A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873–1881. doi:10.1001/jama.2011.593 PubMedCrossRef

31.

Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460):671–679. doi:10.1016/s0140-6736(05)17947-1 PubMedCrossRef

32.

Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genom 9:239. doi:10.1186/1471-2164-9-239 CrossRef

33.

Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L (2010) Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 28(27):4111–4119. doi:10.1200/jco.2010.28.4273 PubMedCentralPubMedCrossRef

34.

Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedren S, Bergh J (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res : BCR 7(6):R953–R964. doi:10.1186/bcr1325 PubMedCentralPubMedCrossRef

35.

Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102(38):13550–13555. doi:10.1073/pnas.0506230102 PubMedCentralPubMedCrossRef

36.

Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33(1):49–54. doi:10.1038/ng1060 PubMedCrossRef

37.

Koboldt DC et al (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70. doi:10.1038/nature11412 CrossRef

38.

Davies M, Robinson M, Smith E, Huntley S, Prime S, Paterson I (2005) Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J Cell Biochem 95(5):918–931. doi:10.1002/jcb.20458 PubMedCrossRef

39.

Han G, Lu SL, Li AG, He W, Corless CL, Kulesz-Martin M, Wang XJ (2005) Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Investig 115(7):1714–1723. doi:10.1172/jci24399 PubMedCentralPubMedCrossRef

40.

Bachman KE, Park BH (2005) Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter. Curr Opin Oncol 17(1):49–54PubMedCrossRef

41.

Moreno-Bueno G, Cubillo E, Sarrio D, Peinado H, Rodriguez-Pinilla SM, Villa S, Bolos V, Jorda M, Fabra A, Portillo F, Palacios J, Cano A (2006) Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res 66(19):9543–9556. doi:10.1158/0008-5472.can-06-0479 PubMedCrossRef

42.

Yilmaz M, Christofori G (2009) EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28(1–2):15–33. doi:10.1007/s10555-008-9169-0 PubMedCrossRef

43.

Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100(9):672–679. doi:10.1093/jnci/djn123 PubMedCrossRef

44.

Tyagi AK, Agarwal C, Chan DC, Agarwal R (2004) Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep 11(2):493–499PubMed

45.

Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17(2):460–469PubMed

46.

Lin FJ, Chen X, Qin J, Hong YK, Tsai MJ, Tsai SY (2010) Direct transcriptional regulation of neuropilin-2 by COUP-TFII modulates multiple steps in murine lymphatic vessel development. J Clin Investig 120(5):1694–1707. doi:10.1172/jci40101 PubMedCentralPubMedCrossRef

47.

Riggs KA, Wickramasinghe NS, Cochrum RK, Watts MB, Klinge CM (2006) Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells. Cancer Res 66(20):10188–10198. doi:10.1158/0008-5472.can-05-3937 PubMedCrossRef

48.

Song CH, Lee HJ, Park E, Lee K (2012) The chicken ovalbumin upstream promoter-transcription factor II negatively regulates the transactivation of androgen receptor in prostate cancer cells. PLoS ONE 7(11):e49026. doi:10.1371/journal.pone.0049026 PubMedCentralPubMedCrossRef

49.

Hawkins SM, Loomans HA, Wan YW, Ghosh-Choudhury T, Coffey D, Xiao W, Liu Z, Sangi-Haghpeykar H, Anderson ML (2013) Expression and functional pathway analysis of nuclear receptor NR2F2 in ovarian cancer. J Clin Endocrinol Metab 98(7):E1152–E1162. doi:10.1210/jc.2013-1081 PubMedCentralPubMedCrossRef

50.

Wu SP, Cheng CM, Lanz RB, Wang T, Respress JL, Ather S, Chen W, Tsai SJ, Wehrens XH, Tsai MJ, Tsai SY (2013) Atrial identity is determined by a COUP-TFII regulatory network. Dev Cell 25(4):417–426. doi:10.1016/j.devcel.2013.04.017 PubMedCentralPubMedCrossRef

51.

Fernandez-Rachubinski F, Fliegel L (2001) COUP-TFI and COUP-TFII regulate expression of the NHE through a nuclear hormone responsive element with enhancer activity. Eur J Biochem 268(3):620–634PubMedCrossRef

52.

Kalluri R (2009) EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Investig 119(6):1417–1419. doi:10.1172/jci39675 PubMedCentralPubMedCrossRef

53.

Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454. doi:10.1038/nrc822 PubMedCrossRef

54.

Miettinen PJ, Ebner R, Lopez AR, Derynck R (1994) TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 127(6 Pt 2):2021–2036PubMedCrossRef

55.

Moustakas A, Heldin CH (2007) Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98(10):1512–1520. doi:10.1111/j.1349-7006.2007.00550.x PubMedCrossRef

56.

Dumont N, Arteaga CL (2003) Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 3(6):531–536PubMedCrossRef

57.

Yingling JM, Blanchard KL, Sawyer JS (2004) Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 3(12):1011–1022. doi:10.1038/nrd1580 PubMedCrossRef

58.

Izumiya M, Kabashima A, Higuchi H, Igarashi T, Sakai G, Iizuka H, Nakamura S, Adachi M, Hamamoto Y, Funakoshi S, Takaishi H, Hibi T (2012) Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells. Anticancer Res 32(9):3847–3853PubMed

59.

Zhang H, Wu H, Zheng J, Yu P, Xu L, Jiang P, Gao J, Wang H, Zhang Y (2013) Transforming growth factor beta1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma. Stem cells (Dayton, Ohio) 31(3):433–446. doi:10.1002/stem.1298 CrossRef

60.

Yamada D, Kobayashi S, Wada H, Kawamoto K, Marubashi S, Eguchi H, Ishii H, Nagano H, Doki Y, Mori M (2013) Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. Eur J Cancer 49(7):1725–1740. doi:10.1016/j.ejca.2012.12.002 PubMedCrossRef

61.

Chen WC, Lai YA, Lin YC, Ma JW, Huang LF, Yang NS, Ho CT, Kuo SC, Way TD (2013) Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of TGF-beta and PI3 K/AKT signaling pathways in triple-negative breast cancer cells. J Agric Food Chem 61(48):11817–11824. doi:10.1021/jf404092f PubMedCrossRef

62.

Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, De K, Sun LZ (2010) Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS ONE 5(4):e10365. doi:10.1371/journal.pone.0010365 PubMedCentralPubMedCrossRef

63.

Iseri OD, Kars MD, Arpaci F, Atalay C, Pak I, Gunduz U (2011) Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother 65(1):40–45. doi:10.1016/j.biopha.2010.10.004 PubMedCrossRef

Title: High NR2F2 transcript level is associated with increased survival and its expression inhibits TGF-β-dependent epithelial-mesenchymal transition in breast cancer
Authors: Cheng Zhang
Yong Han
Hao Huang
Like Qu
Chengchao Shou
Publication date: 01-09-2014
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-014-3095-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: Are signal intensity–time curves adequate?

Outcomes of solid palpable masses assessed as BI-RADS 3 or 4A: a retrospective review

Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs

Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation

Digital compared to screen-film mammography: breast cancer prognostic features in an organized screening program

Author’s response to “Letter to the editor: unvalidated antibodies and misleading results”

Keynote webinar | Spotlight on antibody–drug conjugates in cancer